Pfizer Inc. (PFE)
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
Pfizer (PFE) concluded the recent trading session at $27.1, signifying a -2.62% move from its prior day's close.
Why Pfizer (PFE) Outpaced the Stock Market Today
In the most recent trading session, Pfizer (PFE) closed at $28.55, indicating a +1.67% shift from the previous trading day.
PFE Stock Trades Above 200 & 50-Day SMA for 3 Months: How to Play
Pfizer's PFE stock has been trading steadily above its 50-day and 200-day simple moving averages (SMAs) since early January, signaling sustained investor confidence. The stock is also up about 12.8% so far in 2026.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer: Why Wall Street Habitually Overestimates Target Price
Pfizer Inc. (PFE) currently receives a buy rating from Wall Street, but I believe the rating is overoptimistic. Political uncertainties around 'TrumpRx' and 'Most-Favored-Nation' drug pricing models continue to threaten PFE's margins and valuation outlook. PFE's FWD P/E of 9.3x appears attractive on the surface, but is actually not once the multi-year earnings decline risks are factored in.
Why Pfizer Remains A Strong Buy In 2026
Pfizer started 2026 on a high note despite ongoing skepticism from retail investors. Its key anti-cancer drugs, Padcev, Lorbrena, and Talzenna, showed strong performance in Q4. Accordingly, sales of Talzenna rose 81.5% year-on-year to $49 million.
Why the Market Dipped But Pfizer (PFE) Gained Today
In the closing of the recent trading day, Pfizer (PFE) stood at $27.57, denoting a +1.06% move from the preceding trading day.
Income Investors Face a Hard Truth About Pfizer's Payout Safety
Pfizer (NYSE: PFE) is one of the most widely held dividend stocks among retirement investors.
This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven't Priced In
It's rare to get such a massive high-yielder that's also positioning itself for long-term growth.
Pfizer: Time To Buy The Turnaround
Pfizer remains a compelling value with a Strong Buy rating, driven by robust oncology pipeline progress and the Seagen acquisition. PFE's valuation is highly attractive, trading at a P/E of 8.35 and offering a 6.38% yield, with fair value estimated at $35 per share. Recent clinical wins in oncology and a promising obesity pipeline position PFE for long-term growth despite looming patent cliffs.
Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial
Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year.
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial
Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study of a vaccine candidate for Lyme disease.
